{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:32:11Z","timestamp":1794537131242,"version":"4.9.1"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41417-026-01033-8","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T18:12:27Z","timestamp":1777313547000},"page":"479-491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Application of CAR-T therapy in solid tumors: current opportunities and challenges"],"prefix":"10.1038","volume":"33","author":[{"given":"Aixin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3836-5107","authenticated-orcid":false,"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"1033_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1033_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer J. 2021;11:69.","journal-title":"Blood Cancer J"},{"key":"1033_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107419","volume":"205","author":"SJ Bagley","year":"2020","unstructured":"Bagley SJ, O\u2019Rourke DM. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions. Pharm Ther. 2020;205:107419.","journal-title":"Pharm Ther"},{"key":"1033_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/jha2.356","volume":"3","author":"U Patel","year":"2022","unstructured":"Patel U, Abernathy J, Savani BN, Oluwole O, Sengsayadeth S, Dholaria B. CAR T cell therapy in solid tumors: A review of current clinical trials. EJHaem. 2022;3:24\u201331.","journal-title":"EJHaem"},{"key":"1033_CR5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1080\/02648725.2018.1430465","volume":"33","author":"N Muhammad","year":"2017","unstructured":"Muhammad N, Mao Q, Xia H. CAR T-cells for cancer therapy. Biotechnol Genet Eng Rev. 2017;33:190\u2013226.","journal-title":"Biotechnol Genet Eng Rev"},{"key":"1033_CR6","doi-asserted-by":"publisher","first-page":"517","DOI":"10.54097\/hset.v54i.9841","volume":"54","author":"J Zheng","year":"2023","unstructured":"Zheng J. CAR T-cell therapy in solid tumors: Current review and future perspectives. HSET. 2023;54:517\u201327.","journal-title":"HSET"},{"key":"1033_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s12254-021-00703-7","volume":"14","author":"\u00d6 Umut","year":"2021","unstructured":"Umut \u00d6, Gottschlich A, Endres S, Kobold S. CAR T cell therapy in solid tumors: A short review. Memo. 2021;14:143\u20139.","journal-title":"Memo"},{"key":"1033_CR8","doi-asserted-by":"publisher","first-page":"E27726215340105","DOI":"10.2174\/0127726215340105250124053210","volume":"1","author":"D Karati","year":"2025","unstructured":"Karati D, Sarkar S, Kundu M, Majumder P, Biswas A, Mondal T, et al. CAR-T cell therapy: Illuminating the path to solid tumour recovery. Curr Cell Sci. 2025;1:E27726215340105.","journal-title":"Curr Cell Sci"},{"key":"1033_CR9","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.54097\/4y6n1x07","volume":"74","author":"Y Zeng","year":"2023","unstructured":"Zeng Y. Progress and prospects of CAR-T therapy for the treatment of solid tumors. Highlights Sci, Eng Technol. 2023;74:1323\u201333.","journal-title":"Highlights Sci, Eng Technol"},{"key":"1033_CR10","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41587-024-02446-2","volume":"43","author":"U Uslu","year":"2025","unstructured":"Uslu U, June CH. Beyond the blood: Expanding CAR T cell therapy to solid tumors. Nat Biotechnol. 2025;43:506\u201315.","journal-title":"Nat Biotechnol"},{"key":"1033_CR11","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12272-019-01136-x","volume":"42","author":"Y-H Lee","year":"2019","unstructured":"Lee Y-H, Kim CH. Evolution of chimeric antigen receptor (CAR) T cell therapy: Current status and future perspectives. Arch Pharm Res. 2019;42:607\u201316.","journal-title":"Arch Pharm Res"},{"key":"1033_CR12","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1051\/medsci\/2024151","volume":"40","author":"D Messaoudi","year":"2024","unstructured":"Messaoudi D, Perez F, Gouveia Z. [the new generations of CAR-T cells]. Med Sci (Paris). 2024;40:848\u201357.","journal-title":"Med Sci (Paris)"},{"key":"1033_CR13","doi-asserted-by":"publisher","first-page":"726","DOI":"10.54254\/2753-8818\/3\/20220448","volume":"3","author":"W Zhang","year":"2023","unstructured":"Zhang W. CAR T cell therapy: Evolutions and emergent improvements. TNS. 2023;3:726\u201336.","journal-title":"TNS"},{"key":"1033_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1448752","volume":"15","author":"J Gallego-Valle","year":"2024","unstructured":"Gallego-Valle J, P\u00e9rez-Fern\u00e1ndez VA, Rosales-Magallares J, Gil-Manso S, Castell\u00e1 M, Gonzalez-Navarro EA, et al. High specificity of engineered T cells with third generation CAR (CD28-4-1BB-CD3-\u03b6) based on biotin-bound monomeric streptavidin for potential tumor immunotherapy. Front Immunol. 2024;15:1448752.","journal-title":"Front Immunol"},{"key":"1033_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1090959","volume":"13","author":"S Thomas","year":"2022","unstructured":"Thomas S, Abken H. CAR T cell therapy becomes CHIC: \u2018cytokine help intensified CAR\u2019 T cells. Front Immunol. 2022;13:1090959.","journal-title":"Front Immunol"},{"key":"1033_CR16","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.3390\/cancers15133476","volume":"15","author":"Z Zheng","year":"2023","unstructured":"Zheng Z, Li S, Liu M, Chen C, Zhang L, Zhou D. Fine-tuning through generations: Advances in structure and production of CAR-T therapy. Cancers (Basel). 2023;15:3476.","journal-title":"Cancers (Basel)"},{"key":"1033_CR17","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","volume":"164","author":"KT Roybal","year":"2016","unstructured":"Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell. 2016;164:770\u20139.","journal-title":"Cell"},{"key":"1033_CR18","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","volume":"5","author":"VD Fedorov","year":"2013","unstructured":"Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013;5:215ra172.","journal-title":"Sci Transl Med"},{"key":"1033_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nbt.2459","volume":"31","author":"CC Kloss","year":"2013","unstructured":"Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 2013;31:71\u201375.","journal-title":"Nat Biotechnol"},{"key":"1033_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","volume":"12","author":"S Guedan","year":"2019","unstructured":"Guedan S, Calderon H, Posey AD, Maus MV. Engineering and design of chimeric antigen receptors. Mol Ther Methods Clin Dev. 2019;12:145\u201356.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1033_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00371-7","volume":"10","author":"P Safarzadeh Kozani","year":"2022","unstructured":"Safarzadeh Kozani P, Naseri A, Mirarefin SMJ, Salem F, Nikbakht M, Evazi Bakhshi S, et al. Nanobody-based CAR-T cells for cancer immunotherapy. Biomark Res. 2022;10:24.","journal-title":"Biomark Res"},{"key":"1033_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","volume":"34","author":"I Jov\u010devska","year":"2020","unstructured":"Jov\u010devska I, Muyldermans S. The therapeutic potential of nanobodies. BioDrugs. 2020;34:11\u201326.","journal-title":"BioDrugs"},{"key":"1033_CR23","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","volume":"18","author":"DL Wagner","year":"2021","unstructured":"Wagner DL, Fritsche E, Pulsipher MA, Ahmed N, Hamieh M, Hegde M, et al. Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol. 2021;18:379\u201393.","journal-title":"Nat Rev Clin Oncol"},{"key":"1033_CR24","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","volume":"26","author":"JN Brudno","year":"2020","unstructured":"Brudno JN, Lam N, Vanasse D, Shen Y-W, Rose JJ, Rossi J, et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat Med. 2020;26:270\u201380.","journal-title":"Nat Med"},{"key":"1033_CR25","doi-asserted-by":"publisher","first-page":"200","DOI":"10.54254\/2753-8818\/3\/20220232","volume":"3","author":"X Lu","year":"2023","unstructured":"Lu X. Structural and research advances in CAR-T cell therapy. TNS. 2023;3:200\u20135.","journal-title":"TNS"},{"key":"1033_CR26","doi-asserted-by":"publisher","first-page":"e15080","DOI":"10.1200\/JCO.2024.42.16_suppl.e15080","volume":"42","author":"W Wesson","year":"2024","unstructured":"Wesson W, Ayoobkhan FS, Mahmoudjafari Z, Mushtaq MU, Abdallah A-OA, Sun W, et al. Characterizing clinical trials for CAR T targeting solid tumors from 2018 to 2023: A systematic review. JCO. 2024;42:e15080.","journal-title":"JCO"},{"key":"1033_CR27","first-page":"189","volume":"4","author":"S Zhu","year":"2024","unstructured":"Zhu S. CAR-T in cancer therapeutics and updates. J Natl Cancer Cent. 2024;4:189\u201394.","journal-title":"J Natl Cancer Cent"},{"key":"1033_CR28","first-page":"96","volume":"52","author":"LT Tony","year":"2025","unstructured":"Tony LT, Stabile A, Schauer MP, Hudecek M, Weber J. CAR-T cell therapy for solid tumors. Transfus Med Hemother. 2025;52:96\u2013108.","journal-title":"Transfus Med Hemother"},{"key":"1033_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104648","volume":"209","author":"DA Mart\u00ednez-Gamboa","year":"2025","unstructured":"Mart\u00ednez-Gamboa DA, Hans R, Moreno-Cortes E, Figueroa-Aguirre J, Garcia-Robledo JE, Vargas-Cely F, et al. CAR T-cell therapy landscape in pediatric, adolescent and young adult oncology - a comprehensive analysis of clinical trials. Crit Rev Oncol Hematol. 2025;209:104648.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1033_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202414882","volume":"37","author":"D Zhu","year":"2025","unstructured":"Zhu D, Kim WJ, Lee H, Bao X, Kim P. Engineering CAR-T therapeutics for enhanced solid tumor targeting. Adv Mater. 2025;37:e2414882.","journal-title":"Adv Mater"},{"key":"1033_CR31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda SM. CAR T cell therapy for patients with solid tumours: Key lessons to learn and unlearn. Nat Rev Clin Oncol. 2024;21:47\u201366.","journal-title":"Nat Rev Clin Oncol"},{"key":"1033_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108763","volume":"266","author":"K Misawa","year":"2025","unstructured":"Misawa K, Bhat H, Adusumilli PS, Hou Z. Combinational CAR T-cell therapy for solid tumors: Requisites, rationales, and trials. Pharm Ther. 2025;266:108763.","journal-title":"Pharm Ther"},{"key":"1033_CR33","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.1016\/S1470-2045(19)30461-9","volume":"20","author":"I Minn","year":"2019","unstructured":"Minn I, Rowe SP, Pomper MG. Enhancing CAR T-cell therapy through cellular imaging and radiotherapy. Lancet Oncol. 2019;20:e443\u2013e451.","journal-title":"Lancet Oncol"},{"key":"1033_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0278-6","volume":"9","author":"MM D\u2019Aloia","year":"2018","unstructured":"D\u2019Aloia MM, Zizzari IG, Sacchetti B, Pierelli L, Alimandi M. CAR-T cells: The long and winding road to solid tumors. Cell Death Dis. 2018;9:282.","journal-title":"Cell Death Dis"},{"key":"1033_CR35","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.pharmthera.2016.06.010","volume":"166","author":"GL Beatty","year":"2016","unstructured":"Beatty GL, O\u2019Hara M. Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps. Pharm Ther. 2016;166:30\u20139.","journal-title":"Pharm Ther"},{"key":"1033_CR36","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843\u201351.","journal-title":"Mol Ther"},{"key":"1033_CR37","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/mt.2010.272","volume":"19","author":"MR Parkhurst","year":"2011","unstructured":"Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan D-AN, Feldman SA, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011;19:620\u20136.","journal-title":"Mol Ther"},{"key":"1033_CR38","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi G, Fraietta JA, Gerson JN, Van Deerlin VM, Morrissette JJD, Caponetti GC, et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med. 2024;30:984\u20139.","journal-title":"Nat Med"},{"key":"1033_CR39","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1172\/JCI32949","volume":"117","author":"FD Bushman","year":"2007","unstructured":"Bushman FD. Retroviral integration and human gene therapy. J Clin Invest. 2007;117:2083\u20136.","journal-title":"J Clin Invest"},{"key":"1033_CR40","first-page":"985","volume":"17","author":"AA Ben","year":"2021","unstructured":"Ben AA, Niculescu M-V, Migliorini D. [CAR-T cells in solid tumours: Present and future]. Rev Med Suisse. 2021;17:985\u201393.","journal-title":"Rev Med Suisse"},{"key":"1033_CR41","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s10555-024-10213-7","volume":"43","author":"C Sirini","year":"2024","unstructured":"Sirini C, De Rossi L, Moresco MA, Casucci M. CAR T cells in solid tumors and metastasis: Paving the way forward. Cancer Metastasis Rev. 2024;43:1279\u201396.","journal-title":"Cancer Metastasis Rev"},{"key":"1033_CR42","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/14712598.2020.1738378","volume":"20","author":"S Ramakrishna","year":"2020","unstructured":"Ramakrishna S, Barsan V, Mackall C. Prospects and challenges for use of CAR T cell therapies in solid tumors. Expert Opin Biol Ther. 2020;20:503\u201316.","journal-title":"Expert Opin Biol Ther"},{"key":"1033_CR43","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","volume":"25","author":"G Guzman","year":"2023","unstructured":"Guzman G, Reed MR, Bielamowicz K, Koss B, Rodriguez A. CAR-T therapies in solid tumors: Opportunities and challenges. Curr Oncol Rep. 2023;25:479\u201389.","journal-title":"Curr Oncol Rep"},{"key":"1033_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1489827","volume":"15","author":"SH Khan","year":"2024","unstructured":"Khan SH, Choi Y, Veena M, Lee JK, Shin DS. Advances in CAR T cell therapy: Antigen selection, modifications, and current trials for solid tumors. Front Immunol. 2024;15:1489827.","journal-title":"Front Immunol"},{"key":"1033_CR45","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.54097\/srya2x22","volume":"74","author":"M Lyu","year":"2023","unstructured":"Lyu M. CAR-T cell therapy in solid tumor. Highlights Sci, Eng Technol. 2023;74:1421\u20135.","journal-title":"Highlights Sci, Eng Technol"},{"key":"1033_CR46","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.3390\/ijms25084170","volume":"25","author":"J Rojas-Quintero","year":"2024","unstructured":"Rojas-Quintero J, D\u00edaz MP, Palmar J, Galan-Freyle NJ, Morillo V, Escalona D, et al. Car T cells in solid tumors: Overcoming obstacles. Int J Mol Sci. 2024;25:4170.","journal-title":"Int J Mol Sci"},{"key":"1033_CR47","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1158\/1078-0432.CCR-19-1835","volume":"26","author":"G Fuc\u00e0","year":"2020","unstructured":"Fuc\u00e0 G, Reppel L, Landoni E, Savoldo B, Dotti G. Enhancing chimeric antigen receptor T-cell efficacy in solid tumors. Clin Cancer Res. 2020;26:2444\u201351.","journal-title":"Clin Cancer Res"},{"key":"1033_CR48","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1777064","volume":"9","author":"M Alcantara","year":"2020","unstructured":"Alcantara M, Du Rusquec P, Romano E. Current clinical evidence and potential solutions to increase benefit of CAR T-cell therapy for patients with solid tumors. Oncoimmunology. 2020;9:1777064.","journal-title":"Oncoimmunology"},{"key":"1033_CR49","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","volume":"10","author":"M Martinez","year":"2019","unstructured":"Martinez M, Moon EK. CAR T cells for solid tumors: New strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol. 2019;10:128.","journal-title":"Front Immunol"},{"key":"1033_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738456","volume":"12","author":"N Ghahri-Saremi","year":"2021","unstructured":"Ghahri-Saremi N, Akbari B, Soltantoyeh T, Hadjati J, Ghassemi S, Mirzaei HR. Genetic modification of cytokine signaling to enhance efficacy of CAR T cell therapy in solid tumors. Front Immunol. 2021;12:738456.","journal-title":"Front Immunol"},{"key":"1033_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202009489","volume":"31","author":"R Fu","year":"2021","unstructured":"Fu R, Li H, Li R, McGrath K, Dotti G, Gu Z. Delivery techniques for enhancing CAR T cell therapy against solid tumors. Adv Funct Mater. 2021;31:2009489.","journal-title":"Adv Funct Mater"},{"key":"1033_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188701","volume":"1877","author":"P Akbari","year":"2022","unstructured":"Akbari P, Katsarou A, Daghighian R, van Mil LWHG, Huijbers EJM, Griffioen AW, et al. Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors. Biochim Biophys Acta Rev Cancer. 2022;1877:188701.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1033_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1172681","volume":"14","author":"S Das","year":"2023","unstructured":"Das S, Valton J, Duchateau P, Poirot L. Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy. Front Immunol. 2023;14:1172681.","journal-title":"Front Immunol"},{"key":"1033_CR54","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1080\/07388551.2021.1988509","volume":"42","author":"P Safarzadeh Kozani","year":"2022","unstructured":"Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. Addressing the obstacles of CAR T cell migration in solid tumors: Wishing a heavy traffic. Crit Rev Biotechnol. 2022;42:1079\u201398.","journal-title":"Crit Rev Biotechnol"},{"key":"1033_CR55","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","volume":"25","author":"LA Kankeu Fonkoua","year":"2022","unstructured":"Kankeu Fonkoua LA, Sirpilla O, Sakemura R, Siegler EL, Kenderian SS. CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities. Mol Ther Oncolytics. 2022;25:69\u201377.","journal-title":"Mol Ther Oncolytics"},{"key":"1033_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41282-x","volume":"14","author":"Y Wang","year":"2023","unstructured":"Wang Y, Drum DL, Sun R, Zhang Y, Chen F, Sun F, et al. Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment. Nat Commun. 2023;14:5727.","journal-title":"Nat Commun"},{"key":"1033_CR57","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1158\/2326-6066.CIR-22-0840","volume":"11","author":"HT Quach","year":"2023","unstructured":"Quach HT, Skovgard MS, Villena-Vargas J, Bellis RY, Chintala NK, Amador-Molina A, et al. Tumor-targeted nonablative radiation promotes solid tumor CAR T-cell therapy efficacy. Cancer Immunol Res. 2023;11:1314\u201331.","journal-title":"Cancer Immunol Res"},{"key":"1033_CR58","doi-asserted-by":"publisher","first-page":"253","DOI":"10.54097\/pfsjee15","volume":"102","author":"D Song","year":"2024","unstructured":"Song D. Epigenetic strategies to optimize CAR-T therapy. HSET. 2024;102:253\u20139.","journal-title":"HSET"},{"key":"1033_CR59","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-020-00890-6","volume":"13","author":"Y Tian","year":"2020","unstructured":"Tian Y, Li Y, Shao Y, Zhang Y. Gene modification strategies for next-generation CAR T cells against solid cancers. J Hematol Oncol. 2020;13:54.","journal-title":"J Hematol Oncol"},{"key":"1033_CR60","doi-asserted-by":"publisher","first-page":"10828","DOI":"10.3390\/ijms221910828","volume":"22","author":"V Pietrobon","year":"2021","unstructured":"Pietrobon V, Todd LA, Goswami A, Stefanson O, Yang Z, Marincola F. Improving CAR T-cell persistence. Int J Mol Sci. 2021;22:10828.","journal-title":"Int J Mol Sci"},{"key":"1033_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1412731","volume":"15","author":"S Srinivasan","year":"2024","unstructured":"Srinivasan S, Armitage J, Nilsson J, Waithman J. Transcriptional rewiring in CD8+ T cells: Implications for CAR-T cell therapy against solid tumours. Front Immunol. 2024;15:1412731.","journal-title":"Front Immunol"},{"key":"1033_CR62","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"DM O\u2019Rourke","year":"2017","unstructured":"O\u2019Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9:eaaa0984.","journal-title":"Sci Transl Med"},{"key":"1033_CR63","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh L, Mackall CL. CAR immune cells: Design principles, resistance and the next generation. Nature. 2023;614:635\u201348.","journal-title":"Nature"},{"key":"1033_CR64","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/ajh.26160","volume":"96","author":"S Liu","year":"2021","unstructured":"Liu S, Deng B, Yin Z, Lin Y, An L, Liu D, et al. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. Am J Hematol. 2021;96:671\u20139.","journal-title":"Am J Hematol"},{"key":"1033_CR65","doi-asserted-by":"publisher","unstructured":"Chen J, Jiang H Current challenges and strategies for chimeric antigen receptor-T-cell therapy for solid tumors. CRI 2021; 41. https:\/\/doi.org\/10.1615\/CritRevImmunol.2020036178.","DOI":"10.1615\/CritRevImmunol.2020036178"},{"key":"1033_CR66","doi-asserted-by":"publisher","first-page":"239","DOI":"10.21147\/j.issn.1000-9604.2023.03.03","volume":"35","author":"S Liu","year":"2023","unstructured":"Liu S, Zhang Y. Challenges and interventions of chimeric antigen receptor-T cell therapy in solid tumors. Chin J Cancer Res. 2023;35:239\u201344.","journal-title":"Chin J Cancer Res"},{"key":"1033_CR67","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3390\/cancers14030571","volume":"14","author":"JA Kyte","year":"2022","unstructured":"Kyte JA. Strategies for improving the efficacy of CAR T cells in solid cancers. Cancers (Basel). 2022;14:571.","journal-title":"Cancers (Basel)"},{"key":"1033_CR68","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley SJ, Logun M, Fraietta JA, Wang X, Desai AS, Bagley LJ, et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: Phase 1 trial interim results. Nat Med. 2024;30:1320\u20139.","journal-title":"Nat Med"},{"key":"1033_CR69","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, et al. Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma. N Engl J Med. 2024;390:1290\u20138.","journal-title":"N Engl J Med"},{"key":"1033_CR70","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","volume":"37","author":"BD Choi","year":"2019","unstructured":"Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019;37:1049\u201358.","journal-title":"Nat Biotechnol"},{"key":"1033_CR71","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","volume":"173","author":"JH Cho","year":"2018","unstructured":"Cho JH, Collins JJ, Wong WW. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell. 2018;173:1426\u20131438.e11.","journal-title":"Cell"},{"key":"1033_CR72","doi-asserted-by":"publisher","DOI":"10.1126\/science.aab4077","volume":"350","author":"C-Y Wu","year":"2015","unstructured":"Wu C-Y, Roybal KT, Puchner EM, Onuffer J, Lim WA. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science. 2015;350:aab4077.","journal-title":"Science"},{"key":"1033_CR73","doi-asserted-by":"publisher","first-page":"E459","DOI":"10.1073\/pnas.1524155113","volume":"113","author":"DT Rodgers","year":"2016","unstructured":"Rodgers DT, Mazagova M, Hampton EN, Cao Y, Ramadoss NS, Hardy IR, et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci USA. 2016;113:E459\u2013468.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1033_CR74","doi-asserted-by":"publisher","first-page":"E450","DOI":"10.1073\/pnas.1524193113","volume":"113","author":"JSY Ma","year":"2016","unstructured":"Ma JSY, Kim JY, Kazane SA, Choi S-H, Yun HY, Kim MS, et al. Versatile strategy for controlling the specificity and activity of engineered T cells. Proc Natl Acad Sci USA. 2016;113:E450\u2013458.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1033_CR75","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1158\/1078-0432.CCR-12-1449","volume":"18","author":"K Tamada","year":"2012","unstructured":"Tamada K, Geng D, Sakoda Y, Bansal N, Srivastava R, Li Z, et al. Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res. 2012;18:6436\u201345.","journal-title":"Clin Cancer Res"},{"key":"1033_CR76","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3390\/cancers9070092","volume":"9","author":"P Sridhar","year":"2017","unstructured":"Sridhar P, Petrocca F. Regional delivery of chimeric antigen receptor (CAR) T-cells for cancer therapy. Cancers (Basel). 2017;9:92.","journal-title":"Cancers (Basel)"},{"key":"1033_CR77","doi-asserted-by":"publisher","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","volume":"6","author":"PS Adusumilli","year":"2014","unstructured":"Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014;6:261ra151.","journal-title":"Sci Transl Med"},{"key":"1033_CR78","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jss.2021.11.001","volume":"272","author":"LF Chai","year":"2022","unstructured":"Chai LF, Hardaway JC, Heatherton KR, O\u2019Connell KP, LaPorte JP, Guha P, et al. Antigen receptor T cells (CAR-T) effectively control tumor growth in a colorectal liver metastasis model. J Surg Res. 2022;272:37\u201350.","journal-title":"J Surg Res"},{"key":"1033_CR79","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ccell.2022.04.006","volume":"40","author":"L Cherkassky","year":"2022","unstructured":"Cherkassky L, Hou Z, Amador-Molina A, Adusumilli PS. Regional CAR T cell therapy: An ignition key for systemic immunity in solid tumors. Cancer Cell. 2022;40:569\u201374.","journal-title":"Cancer Cell"},{"key":"1033_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106329","volume":"182","author":"SM Sagnella","year":"2022","unstructured":"Sagnella SM, White AL, Yeo D, Saxena P, van Zandwijk N, Rasko JEJ. Locoregional delivery of CAR-T cells in the clinic. Pharm Res. 2022;182:106329.","journal-title":"Pharm Res"},{"key":"1033_CR81","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3390\/cancers11050674","volume":"11","author":"LM Whilding","year":"2019","unstructured":"Whilding LM, Halim L, Draper B, Parente-Pereira AC, Zabinski T, Davies DM, et al. CAR T-cells targeting the integrin \u03b1v\u03b26 and co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies. Cancers (Basel). 2019;11:674.","journal-title":"Cancers (Basel)"},{"key":"1033_CR82","doi-asserted-by":"publisher","unstructured":"Hosking M, Shirinbak S, Grant J, Pan Y, Gentile A, Mehta A et al. 120 chemokine receptor engineering enhances trafficking and homing of primary and iPSC-derived CAR-T cells to solid tumors. J Immunother Cancer 2021;9. https:\/\/doi.org\/10.1136\/jitc-2021-SITC2021.120.","DOI":"10.1136\/jitc-2021-SITC2021.120"},{"key":"1033_CR83","doi-asserted-by":"publisher","unstructured":"Cadilha BL, Dorman K, Huynh D, Lorenzini T, V\u00e4nttinen M, Benmebarek M-R et al. P06.03 C-C chemokine receptor 8 tumor-directed recruitment enables CAR T cells to reject solid tumors. J Immunother Cancer 2020;8. https:\/\/doi.org\/10.1136\/jitc-2020-ITOC7.82.","DOI":"10.1136\/jitc-2020-ITOC7.82"},{"key":"1033_CR84","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202401161","volume":"34","author":"W Wan","year":"2024","unstructured":"Wan W, Han W, Chen J, Li Y, Zhao L, Gao M, et al. Chemokine-based injectable navigation system for enhancing CAR-T cell therapy against solid tumors. Adv Funct Mater. 2024;34:2401161.","journal-title":"Adv Funct Mater"},{"key":"1033_CR85","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202407425","volume":"37","author":"Q Zou","year":"2025","unstructured":"Zou Q, Liao K, Li G, Huang X, Zheng Y, Yang G, et al. Photo-metallo-immunotherapy: Fabricating chromium-based nanocomposites to enhance CAR-T cell infiltration and cytotoxicity against solid tumors. Adv Mater. 2025;37:e2407425.","journal-title":"Adv Mater"},{"key":"1033_CR86","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","volume":"21","author":"SC Katz","year":"2015","unstructured":"Katz SC, Burga RA, McCormack E, Wang LJ, Mooring W, Point GR, et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin Cancer Res. 2015;21:3149\u201359.","journal-title":"Clin Cancer Res"},{"key":"1033_CR87","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375:2561\u20139.","journal-title":"N Engl J Med"},{"key":"1033_CR88","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jinf.2013.11.014","volume":"68","author":"PA Mead","year":"2014","unstructured":"Mead PA, Safdieh JE, Nizza P, Tuma S, Sepkowitz KA. Ommaya reservoir infections: A 16-year retrospective analysis. J Infect. 2014;68:225\u201330.","journal-title":"J Infect"},{"key":"1033_CR89","first-page":"10","volume":"4","author":"A Ali","year":"2019","unstructured":"Ali A, Bosse RC, Doonan BP, Narayan P, Jester GA, Delaune JD, et al. Ommaya reservoir related complications: A single center experience and review of current literature. Int J Clin Oncol Cancer Res. 2019;4:10\u201324.","journal-title":"Int J Clin Oncol Cancer Res"},{"key":"1033_CR90","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri.2017.49","volume":"17","author":"N Nagarsheth","year":"2017","unstructured":"Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17:559\u201372.","journal-title":"Nat Rev Immunol"},{"key":"1033_CR91","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17:147\u201367.","journal-title":"Nat Rev Clin Oncol"},{"key":"1033_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1389971","volume":"15","author":"BP Satapathy","year":"2024","unstructured":"Satapathy BP, Sheoran P, Yadav R, Chettri D, Sonowal D, Dash CP, et al. The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: A systematic review. Front Immunol. 2024;15:1389971.","journal-title":"Front Immunol"},{"key":"1033_CR93","doi-asserted-by":"publisher","first-page":"14780","DOI":"10.3390\/ijms241914780","volume":"24","author":"MA P\u00e9rez-Moreno","year":"2023","unstructured":"P\u00e9rez-Moreno MA, Ciudad-Guti\u00e9rrez P, Jaramillo-Ruiz D, Reguera-Ortega JL, Abdel-Kader Mart\u00edn L, Flores-Moreno S. Combined or sequential treatment with immune checkpoint inhibitors and car-T cell therapies for the management of haematological malignancies: A systematic review. Int J Mol Sci. 2023;24:14780.","journal-title":"Int J Mol Sci"},{"key":"1033_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02079-8","volume":"23","author":"X Xia","year":"2024","unstructured":"Xia X, Yang Z, Lu Q, Liu Z, Wang L, Du J, et al. Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy. Mol Cancer. 2024;23:175.","journal-title":"Mol Cancer"},{"key":"1033_CR95","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41423-021-00655-2","volume":"18","author":"G Liu","year":"2021","unstructured":"Liu G, Rui W, Zhao X, Lin X. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. Cell Mol Immunol. 2021;18:1085\u201395.","journal-title":"Cell Mol Immunol"},{"key":"1033_CR96","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36:847\u201356.","journal-title":"Nat Biotechnol"},{"key":"1033_CR97","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/1078-0432.CCR-20-1457","volume":"27","author":"H Liu","year":"2021","unstructured":"Liu H, Lei W, Zhang C, Yang C, Wei J, Guo Q, et al. CD19-specific CAR T cells that express a PD-1\/CD28 chimeric switch-receptor are effective in patients with PD-L1-positive B-cell lymphoma. Clin Cancer Res. 2021;27:473\u201384.","journal-title":"Clin Cancer Res"},{"key":"1033_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00462-8","volume":"7","author":"LJ Rupp","year":"2017","unstructured":"Rupp LJ, Schumann K, Roybal KT, Gate RE, Ye CJ, Lim WA, et al. CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017;7:737.","journal-title":"Sci Rep"},{"key":"1033_CR99","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13045-021-01044-y","volume":"14","author":"Y Liang","year":"2021","unstructured":"Liang Y, Liu H, Lu Z, Lei W, Zhang C, Li P, et al. CD19 CAR-T expressing PD-1\/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies. J Hematol Oncol. 2021;14:26.","journal-title":"J Hematol Oncol"},{"key":"1033_CR100","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.trecan.2025.08.009","volume":"11","author":"N Kwon","year":"2025","unstructured":"Kwon N, Chen YY. Overcoming solid-tumor barriers: Armored CAR-T cell therapy. Trends Cancer. 2025;11:1019\u201329.","journal-title":"Trends Cancer"},{"key":"1033_CR101","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn RC, Weber EW, Sotillo E, Gennert D, Xu P, Good Z, et al. c-jun overexpression in CAR T cells induces exhaustion resistance. Nature. 2019;576:293\u2013300.","journal-title":"Nature"},{"key":"1033_CR102","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nm.4478","volume":"24","author":"Y Kagoya","year":"2018","unstructured":"Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang C-H, Saso K, et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med. 2018;24:352\u20139.","journal-title":"Nat Med"},{"key":"1033_CR103","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cmet.2015.11.002","volume":"23","author":"M Sukumar","year":"2016","unstructured":"Sukumar M, Liu J, Mehta GU, Patel SJ, Roychoudhuri R, Crompton JG, et al. Mitochondrial membrane potential identifies cells with enhanced stemness for cellular therapy. Cell Metab. 2016;23:63\u201376.","journal-title":"Cell Metab"},{"key":"1033_CR104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1688995","volume":"16","author":"T Frlic","year":"2025","unstructured":"Frlic T, Pavlin M. Metabolic reprogramming of CAR T cells: A new frontier in cancer immunotherapy. Front Immunol. 2025;16:1688995.","journal-title":"Front Immunol"},{"key":"1033_CR105","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar OU, O\u2019Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44:380\u201390.","journal-title":"Immunity"},{"key":"1033_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10940-8","volume":"7","author":"OO Yeku","year":"2017","unstructured":"Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep. 2017;7:10541.","journal-title":"Sci Rep"},{"key":"1033_CR107","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367:eaba7365.","journal-title":"Science"},{"key":"1033_CR108","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00262-014-1523-1","volume":"63","author":"W Lasek","year":"2014","unstructured":"Lasek W, Zago\u017cd\u017con R, Jakobisiak M. Interleukin 12: Still a promising candidate for tumor immunotherapy?. Cancer Immunol Immunother. 2014;63:419\u201335.","journal-title":"Cancer Immunol Immunother"},{"key":"1033_CR109","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","volume":"53","author":"P Vormittag","year":"2018","unstructured":"Vormittag P, Gunn R, Ghorashian S, Veraitch FS. A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol. 2018;53:164\u201381.","journal-title":"Curr Opin Biotechnol"},{"key":"1033_CR110","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2017","unstructured":"Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2017;4:92\u2013101.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1033_CR111","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.32","volume":"2","author":"Z Grada","year":"2013","unstructured":"Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, et al. TanCAR: A novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids. 2013;2:e105.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1033_CR112","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","volume":"4","author":"E Zah","year":"2016","unstructured":"Zah E, Lin M-Y, Silva-Benedict A, Jensen MC, Chen YY. T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res. 2016;4:498\u2013508.","journal-title":"Cancer Immunol Res"},{"key":"1033_CR113","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","volume":"167","author":"KT Roybal","year":"2016","unstructured":"Roybal KT, Williams JZ, Morsut L, Rupp LJ, Kolinko I, Choe JH, et al. Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell. 2016;167:419\u2013432.e16.","journal-title":"Cell"},{"key":"1033_CR114","doi-asserted-by":"publisher","unstructured":"Simeone DM, Hecht JR, Smith C, Fakih M, Welling T, Garon E et al. 636 BASECAMP-1: A master prescreening study to identify patients with high-risk or metastatic solid tumors with HLA loss of heterozygosity (LOH) in preparation for tmod CAR T-cell therapy trials. J Immunother Cancer. 2023;11. https:\/\/doi.org\/10.1136\/jitc-2023-SITC2023.0636.","DOI":"10.1136\/jitc-2023-SITC2023.0636"},{"key":"1033_CR115","doi-asserted-by":"crossref","unstructured":"Larson S First results of IMPT-314, an autologous bispecific CD19\/CD20 chimeric antigen receptor (CAR) in enriched naive and central memory T cells, for the treatment of large B cell lymphoma (LBCL). ASH, 2024 https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper200697.html (accessed 8 Feb2026).","DOI":"10.1182\/blood-2024-200697"},{"key":"1033_CR116","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2312374120","volume":"120","author":"NJ Bangayan","year":"2023","unstructured":"Bangayan NJ, Wang L, Burton Sojo G, Noguchi M, Cheng D, Ta L, et al. Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy. Proc Natl Acad Sci USA. 2023;120:e2312374120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1033_CR117","doi-asserted-by":"publisher","first-page":"e007426","DOI":"10.1136\/jitc-2023-007426","volume":"11","author":"D Bassan","year":"2023","unstructured":"Bassan D, Weinberger L, Yi J, Kim T, Weist MR, Adams GB, et al. HER2 and HLA-a*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity. J Immunother Cancer. 2023;11:e007426.","journal-title":"J Immunother Cancer"},{"key":"1033_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109913","volume":"27","author":"J Oh","year":"2024","unstructured":"Oh J, Kirsh C, Hsin J-P, Radecki KC, Zampieri A, Manry D, et al. NOT gated T cells that selectively target EGFR and other widely expressed tumor antigens. iScience. 2024;27:109913.","journal-title":"iScience"},{"key":"1033_CR119","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi A, Tey S-K, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365:1673\u201383.","journal-title":"N Engl J Med"},{"key":"1033_CR120","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","volume":"105","author":"KC Straathof","year":"2005","unstructured":"Straathof KC, Pul\u00e8 MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005;105:4247\u201354.","journal-title":"Blood"},{"key":"1033_CR121","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N Engl J Med. 2023;388:1284\u201395.","journal-title":"N Engl J Med"},{"key":"1033_CR122","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1182\/blood.2021010784","volume":"137","author":"MC Foster","year":"2021","unstructured":"Foster MC, Savoldo B, Lau W, Rubinos C, Grover N, Armistead P, et al. Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity. Blood. 2021;137:3306\u20139.","journal-title":"Blood"},{"key":"1033_CR123","unstructured":"2025. NCCN Clinical Practice Guidelines in Oncology: Management of CAR T-Cell and Lymphocyte Engager-Related Toxicities. Version 2.2026"},{"key":"1033_CR124","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","volume":"142","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P, et al. Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood. 2023;142:865\u201377.","journal-title":"Blood"},{"key":"1033_CR125","doi-asserted-by":"publisher","first-page":"e007927","DOI":"10.1136\/jitc-2023-007927","volume":"12","author":"GP Botta","year":"2024","unstructured":"Botta GP, Chao J, Ma H, Hahn M, Sierra G, Jia J, et al. Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells. J Immunother Cancer. 2024;12:e007927.","journal-title":"J Immunother Cancer"},{"key":"1033_CR126","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1325860","volume":"15","author":"G Zhong","year":"2024","unstructured":"Zhong G, Zhang X, Guo Z, Gao Y, Zhao B, Liu X, et al. Complete remission of advanced pancreatic cancer induced by claudin18.2-targeted CAR-T cell therapy: A case report. Front Immunol. 2024;15:1325860.","journal-title":"Front Immunol"},{"key":"1033_CR127","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/14712598.2020.1727436","volume":"20","author":"SH Shen","year":"2020","unstructured":"Shen SH, Woroniecka K, Barbour AB, Fecci PE, Sanchez-Perez L, Sampson JH. CAR T cells and checkpoint inhibition for the treatment of glioblastoma. Expert Opin Biol Ther. 2020;20:579\u201391.","journal-title":"Expert Opin Biol Ther"},{"key":"1033_CR128","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1093\/neuonc\/noac024","volume":"24","author":"CE Brown","year":"2022","unstructured":"Brown CE, Rodriguez A, Palmer J, Ostberg JR, Naranjo A, Wagner JR, et al. Off-the-shelf, steroid-resistant, IL13R\u03b12-specific CAR T cells for treatment of glioblastoma. Neuro Oncol. 2022;24:1318\u201330.","journal-title":"Neuro Oncol"},{"key":"1033_CR129","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1158\/2767-9764.CRC-24-0226","volume":"4","author":"K Ohta","year":"2024","unstructured":"Ohta K, Sakoda Y, Adachi K, Shinozaki T, Nakajima M, Yasuda H, et al. Therapeutic efficacy of IL7\/CCL19-expressing CAR-T cells in intractable solid tumor models of glioblastoma and pancreatic cancer. Cancer Res Commun. 2024;4:2514\u201324.","journal-title":"Cancer Res Commun"},{"key":"1033_CR130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12029-020-00457-1","volume":"52","author":"MY Anwar","year":"2021","unstructured":"Anwar MY, Williams GR, Paluri RK. CAR T cell therapy in pancreaticobiliary cancers: A focused review of clinical data. J Gastrointest Cancer. 2021;52:1\u201310.","journal-title":"J Gastrointest Cancer"},{"key":"1033_CR131","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.817296","volume":"13","author":"Y-J Lin","year":"2022","unstructured":"Lin Y-J, Mashouf LA, Lim M. CAR T cell therapy in primary brain tumors: Current investigations and the future. Front Immunol. 2022;13:817296.","journal-title":"Front Immunol"},{"key":"1033_CR132","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3390\/cancers12010125","volume":"12","author":"A Titov","year":"2020","unstructured":"Titov A, Valiullina A, Zmievskaya E, Zaikova E, Petukhov A, Miftakhova R, et al. Advancing CAR T-cell therapy for solid tumors: Lessons learned from lymphoma treatment. Cancers (Basel). 2020;12:125.","journal-title":"Cancers (Basel)"},{"key":"1033_CR133","volume":"13","author":"RS Siddiqui","year":"2021","unstructured":"Siddiqui RS, Sardar M. A systematic review of the role of chimeric antigen receptor T (CAR-T) cell therapy in the treatment of solid tumors. Cureus. 2021;13:e14494.","journal-title":"Cureus"},{"key":"1033_CR134","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.640082","volume":"12","author":"D Mart\u00ednez Bedoya","year":"2021","unstructured":"Mart\u00ednez Bedoya D, Dutoit V, Migliorini D. Allogeneic CAR T cells: An alternative to overcome challenges of CAR T cell therapy in glioblastoma. Front Immunol. 2021;12:640082.","journal-title":"Front Immunol"},{"key":"1033_CR135","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1007\/s00262-021-02856-0","volume":"70","author":"J Huang","year":"2021","unstructured":"Huang J, Zheng M, Zhang Z, Tang X, Chen Y, Peng A, et al. Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma. Cancer Immunol Immunother. 2021;70:2453\u201365.","journal-title":"Cancer Immunol Immunother"},{"key":"1033_CR136","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/14712598.2021.1843628","volume":"21","author":"A Klampatsa","year":"2021","unstructured":"Klampatsa A, Dimou V, Albelda SM. Mesothelin-targeted CAR-T cell therapy for solid tumors. Expert Opin Biol Ther. 2021;21:473\u201386.","journal-title":"Expert Opin Biol Ther"},{"key":"1033_CR137","doi-asserted-by":"publisher","DOI":"10.1101\/2024.10.03.616537","author":"DY Zhang","year":"2024","unstructured":"Zhang DY, Wang X, Sun Y, Cui Q, Nelson E, Zhang Z, et al. Temporal multi-modal single-cell analyses reveal dynamic interactions of CAR. T cells glioblastoma Target antigen-Negat Neoplast cells. 2024. https:\/\/doi.org\/10.1101\/2024.10.03.616537.","journal-title":"T cells glioblastoma Target antigen-Negat Neoplast cells"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01033-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01033-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01033-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T13:25:42Z","timestamp":1782825942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01033-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":137,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1033"],"URL":"https:\/\/doi.org\/10.1038\/s41417-026-01033-8","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Written informed consent for publication was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}